Cancer immunotherapy developer Xilio Therapeutics Inc. has raised $95 million in series C financing to support its efforts to move a duo of tumor-selective candidates into the clinic. IND applications for both its interleukin-2 agonist, XTX-202, and anti-cytotoxic T-lymphocyte-associated protein 4 antibody, XTX-101, are planned for this year.
Chengdu-based Sichuan Clover Biopharmaceuticals Inc., known for its Trimer-Tag technology, raised $230 million in a series C financing round. The proceeds will, most notably, help it advance its COVID-19 vaccine candidate, S-Trimer (SCB-2019), to a global phase II/III trial by June. Following its $43 million series B round in December 2019, Clover said on Tuesday, Feb. 23, that it raised more than $400 million in the last 12 months. The company uses its Trimer-Tag technology platform to produce covalently-trimerized fusion proteins to develop protein-based vaccines and biologic cancer therapies.
LONDON – Exosome specialist Evox Therapeutics Ltd. has raised $95.4 million in a series C round that will enable it to progress a number of rare disease programs into the clinic, with the lead due to enter phase I at the beginning of next year.
LONDON – Advent Life Sciences announced the close of two new transatlantic funds with a total of $215 million, to be dedicated to seed and series A funding of early stage science. The first fund is Advent’s own Life Sciences fund III, while the second is the Advent-Harrington Impact fund, which London-based Advent has raised, and will manage, on behalf of the Harrington Discovery Institute of Cleveland.
RSS
